Clinical Trials Browser

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02668770 2026-04-07

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Phase 1 Terminated

28 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Recurrence

NCT06563804 2026-03-30

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

Phase 1/2 Terminated

13 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06068400 2026-03-17

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma

Phase NA Terminated

1 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04347616 2026-03-16

NK4AML

Phase 1/2 Terminated

9 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05537766 2026-03-10

ZUMA-25

Phase 2 Terminated

19 enrolled 28 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

NCT03211988 2026-03-02

Entinostat Neuroendocrine (NE) Tumor

Phase 2 Terminated

5 enrolled 9 charts

EndocrineNET

Recurrence, Neuroendocrine Tumors

NCT05714345 2026-03-02

EXPAND

Phase 2 Terminated

2 enrolled 8 charts

Lymphoid

Lymphoma, Recurrence

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT04362007 2026-02-25

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Phase 1/2 Terminated

8 enrolled 11 charts

Lymphoid

Lymphoma, Recurrence

NCT02942264 2026-02-23

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Phase 1/2 Terminated

53 enrolled 22 charts

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Recurrence, Gliosarcoma

NCT03374085 2026-02-09

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Phase 1/2 Terminated

200 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04809467 2026-02-04

topMIND

Phase 1/2 Terminated

54 enrolled 23 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05787496 2026-01-28

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Phase 1 Terminated

28 enrolled 19 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07123493 2026-01-28

Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors

Phase EARLY_PHASE1 Terminated

1 enrolled

Recurrence

NCT06193174 2026-01-22

Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)

Phase 1 Terminated

1 enrolled

CNS

Brain Neoplasms, Glioma, Recurrence

NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Phase 2 Terminated

2 enrolled 7 charts

Recurrence

Clinical Trials

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma

NK4AML

ZUMA-25

Entinostat Neuroendocrine (NE) Tumor

EXPAND

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

topMIND

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors

Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas